We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

186 hedge funds and large institutions have $466M invested in PDL BioPharma, Inc. in 2017 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 13

45% more capital invested

Capital invested by funds: $321M → $466M (+$145M)

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

9% more funds holding

Funds holding: 171 → 186 (+15)

37% less call options, than puts

Call options by funds: $450K | Put options by funds: $717K

Holders
186
Holders Change
+15
Holders Change %
+8.77%
% of All Funds
4.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
63
Reduced
44
Closed
13
Calls
$450K
Puts
$717K
Net Calls
-$267K
Net Calls Change
-$555K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$8.55M
2
Morgan Stanley
Morgan Stanley
New York
+$6.49M
3
State Street
State Street
Massachusetts
+$5.81M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$3.96M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.56M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$9.56M
2
Bank of America
Bank of America
North Carolina
-$4.6M
3
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
-$3.61M
4
BlackRock
BlackRock
New York
-$2.18M
5
Deutsche Bank
Deutsche Bank
Germany
-$2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janney Montgomery Scott
151
Janney Montgomery Scott
Pennsylvania
$37K -$556 -200 -2%
CA
152
Cetera Advisors
Colorado
$37K – – –
Wolverine Trading
153
Wolverine Trading
Illinois
$36K +$29.6K +10,643 New
HighTower Advisors
154
HighTower Advisors
Illinois
$36K +$29.7K +10,685 New
FIM
155
Fruth Investment Management
Texas
$34K – – –
Zurich Cantonal Bank
156
Zurich Cantonal Bank
Switzerland
$31K +$12.9K +4,640 +103%
FQ
157
First Quadrant
California
$31K +$25.3K +9,100 New
Group One Trading
158
Group One Trading
Illinois
$28K +$12K +4,300 +107%
QI
159
QS Investors
New York
$21K – – –
EWM
160
Evercore Wealth Management
New York
$20K – – –
TRCT
161
Tower Research Capital (TRC)
New York
$19K +$7.46K +2,684 +89%
AG
162
Advisor Group
Arizona
$16K +$4.28K +1,540 +49%
RA
163
Royce & Associates
New York
$15K +$12K +4,302 New
PNC Financial Services Group
164
PNC Financial Services Group
Pennsylvania
$12K -$2.78K -1,000 -22%
FANJ
165
Financial Architects (New Jersey)
New Jersey
$12K – – –
MAM
166
Meeder Asset Management
Ohio
$12K – – –
First Eagle Investment Management
167
First Eagle Investment Management
New York
$9K – – –
AP
168
Advisors Preferred
Maryland
$8K +$6.24K +2,244 New
HR
169
Howe & Rusling
New York
$7K – – –
WAM
170
Wealthspire Advisors (Maryland)
Maryland
$6K -$512 -184 -9%
IF
171
Ironwood Financial
Arizona
$4K – – –
MCM
172
MV Capital Management
Maryland
$4K +$3.18K +1,143 New
CCM
173
Cribstone Capital Management
Maine
$3K – – –
HNB
174
Huntington National Bank
Ohio
$3K – – –
RE
175
RBC Europe
United Kingdom
$2.79K +$2.29K +824 New
4 5 6
7
8

PDLI Hedge Fund Activity: Q3 2017 in Review

186 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2017, worth a combined $466M — up 45% from $321M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PDLI positions and 13 closed out — a net gain of 18 holders — while 63 added to existing stakes and 44 trimmed.

The largest buyer was Millennium Management, adding an estimated $8.55M. The largest seller was Citadel Advisors, cutting an estimated $9.56M.

  • 186 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2017, up from 171 in Q2 2017.
  • Funds reported $466M of PDL BioPharma, Inc. stock for Q3 2017, up 45% quarter-over-quarter.
  • 31 funds opened new PDL BioPharma, Inc. positions in Q3 2017 and 13 closed out, a net change of +18 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2017 was Millennium Management, an estimated $8.55M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2017 was Citadel Advisors, an estimated $9.56M sold.

Based on aggregated 13F filings for Q3 2017.